For individuals and families affected by ocular melanoma, being told you have a “rare cancer” can feel isolating. It often means fewer treatment options, fewer specialists, and fewer clinical trials than patients diagnosed with more common cancers.
A recent article published in the oncology community explores an interesting question: Should every cancer be considered a rare cancer?
At first glance, the idea may seem surprising. After all, cancers such as breast, lung, and colorectal cancer affect hundreds of thousands of people each year. However, advances in genomic testing are changing how researchers view cancer. Instead of seeing cancer solely by where it begins in the body, scientists are increasingly studying the unique genetic and molecular characteristics that drive each individual tumor.
This shift is especially relevant to the ocular melanoma community.
For years, patients with uveal melanoma have understood the importance of tumor biology. Genetic testing, molecular profiling, and biomarker research have become important tools for understanding disease risk, guiding surveillance, and identifying potential treatment opportunities. What researchers are now suggesting is that many cancers traditionally considered “common” may actually consist of numerous smaller, molecularly distinct diseases that are rare in their own right.
The article argues that modern medicine has entered an era where precision oncology is becoming the standard. Rather than treating all patients with the same type of cancer identically, doctors increasingly tailor treatments based on the specific molecular makeup of a patient’s tumor.
For ocular melanoma patients, this concept offers hope.
As researchers continue to uncover the genetic drivers of cancer, therapies may become more targeted and personalized. Clinical trials may increasingly focus on molecular characteristics rather than cancer location alone, potentially creating new opportunities for patients with rare cancers.
The authors also caution against simply labeling every cancer as “rare.” Doing so could unintentionally divert resources away from truly ultra-rare cancers that already struggle to receive research funding and drug development attention. Instead, they propose a more flexible system that recognizes different levels of rarity while encouraging broader use of genomic testing and personalized treatment approaches.
For patients and caregivers, the most important takeaway is that cancer care continues to evolve. The future is moving toward a model where every patient’s tumor is better understood, not just by its location, but by its unique biology.
For the ocular melanoma community, that future cannot come soon enough.
As molecular profiling becomes more widely available and precision medicine continues to advance, researchers are steadily moving closer to delivering the right treatment to the right patient at the right time. While challenges remain, this article highlights an encouraging reality: rare cancer patients are helping shape the future of cancer care for everyone.